TransCode Therapeutics (NASDAQ:RNAZ) dropped 29% after the upcoming RNA oncology company priced its initial public offering (IPO) of 6.25 million common shares at $4 per share. The company expects gross proceeds of around $25 million before accounting for offering expenses and underwriting commissions and discounts. Also, the company has given underwriters 45 days to acquire …